IL308052A - Topoisomerase I inhibitor conjugate peptide dose transmitters - Google Patents

Topoisomerase I inhibitor conjugate peptide dose transmitters

Info

Publication number
IL308052A
IL308052A IL308052A IL30805223A IL308052A IL 308052 A IL308052 A IL 308052A IL 308052 A IL308052 A IL 308052A IL 30805223 A IL30805223 A IL 30805223A IL 308052 A IL308052 A IL 308052A
Authority
IL
Israel
Prior art keywords
topoisomerase
inhibitors
dosing regimens
peptide conjugates
conjugates
Prior art date
Application number
IL308052A
Other languages
English (en)
Hebrew (he)
Inventor
Vishwas Paralkar
Arthur P Decillis
Original Assignee
Cybrexa 2 Inc
Vishwas Paralkar
Arthur P Decillis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cybrexa 2 Inc, Vishwas Paralkar, Arthur P Decillis filed Critical Cybrexa 2 Inc
Publication of IL308052A publication Critical patent/IL308052A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL308052A 2021-04-29 2022-04-28 Topoisomerase I inhibitor conjugate peptide dose transmitters IL308052A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163181640P 2021-04-29 2021-04-29
PCT/US2022/071967 WO2022232808A1 (en) 2021-04-29 2022-04-28 Dosing regimens of peptide conjugates of topoisomerase i inhibitors

Publications (1)

Publication Number Publication Date
IL308052A true IL308052A (en) 2023-12-01

Family

ID=81749580

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308052A IL308052A (en) 2021-04-29 2022-04-28 Topoisomerase I inhibitor conjugate peptide dose transmitters

Country Status (12)

Country Link
US (1) US20240226308A1 (cg-RX-API-DMAC7.html)
EP (1) EP4329817A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024516825A (cg-RX-API-DMAC7.html)
KR (1) KR20240019097A (cg-RX-API-DMAC7.html)
CN (1) CN117897175A (cg-RX-API-DMAC7.html)
AU (1) AU2022267389A1 (cg-RX-API-DMAC7.html)
CA (1) CA3218253A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003187A1 (cg-RX-API-DMAC7.html)
IL (1) IL308052A (cg-RX-API-DMAC7.html)
MX (1) MX2023012779A (cg-RX-API-DMAC7.html)
TW (1) TW202308696A (cg-RX-API-DMAC7.html)
WO (1) WO2022232808A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
BR112022000297A2 (pt) 2019-07-10 2022-03-15 Cybrexa 3 Inc Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006078816A2 (en) 2005-01-18 2006-07-27 The Board Of Governors For Higher Education Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide
CA3032186C (en) 2010-07-13 2022-04-26 Council on Postsecondary Education, State of Rhode Island and Providence Plantations Environmentally sensitive composition comprising a ph triggered peptide and uses thereof
SG10201913073YA (en) * 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
AU2019205325A1 (en) 2018-01-05 2020-08-13 Cybrexa 1, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
US20210106648A1 (en) * 2019-10-11 2021-04-15 TOBEBIO Novel Drug Laboratory Co., Ltd. Synergistic combination of chemotherapy and peptide for treating cancer

Also Published As

Publication number Publication date
KR20240019097A (ko) 2024-02-14
CA3218253A1 (en) 2022-11-03
AU2022267389A9 (en) 2023-11-16
AU2022267389A1 (en) 2023-11-09
CN117897175A (zh) 2024-04-16
EP4329817A1 (en) 2024-03-06
US20240226308A1 (en) 2024-07-11
MX2023012779A (es) 2024-01-16
WO2022232808A1 (en) 2022-11-03
JP2024516825A (ja) 2024-04-17
CL2023003187A1 (es) 2024-05-03
TW202308696A (zh) 2023-03-01

Similar Documents

Publication Publication Date Title
ES3065149T3 (en) Pharmaceutical composition comprising parp inhibitors
IL289949A (en) Dosing regimens for oral complement factor d inhibitors
IL307188A (en) NLRP3 inhibitors
EP3565599A4 (en) DOSAGE PATTERNS AND DOSAGE FORMS FOR TARGETED INHIBITION OF TGF-B
ZA202102509B (en) Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
IL289658A (en) Peptide conjugates of cytotoxins as therapy
GB202002705D0 (en) Anti-infective bicyclic peptide conjugates
MX352926B (es) Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos.
IL308389A (en) Dosing regimens for acubactadine
PL4313967T3 (pl) Inhibitory khk
EP4358989A4 (en) BICYCLIC PEPTIDYL PAN-RAS INHIBITORS
SG11202104192TA (en) Combination of small molecule cd-47 inhibitors with other anti-cancer agents
SG11201911598WA (en) Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
IL289659A (en) Peptide conjugates of microtubule-targeting agents as therapeutics
IL315886A (en) Dosing regimens for anti-CD19 agents and their uses
MX2023012779A (es) Regimenes de dosificacion de conjugados de peptido de inhibidores de topoisomerasa i.
EP4267264C0 (en) MULTI-COMPONENT PUTTER
HK40108936A (en) Dosing regimens of peptide conjugates of topoisomerase i inhibitors
PT4323338T (pt) Inibidores de tead
IL308095A (en) Dosing regimens
EP4405346A4 (en) SMALL MOLECULE INHIBITORS OF TEAD-YAP
PT4337652T (pt) Inibidores do nlrp3
HK40105571A (zh) Parp7抑制剂的剂量方案
IL326369A (en) Antibody-drug conjugates using two different types of topoisomerase i inhibitors
HK40103557A (en) Dosing regimens for oral alk2 kinase inhibitors